Johnson & Johnson Covid-19 vaccine benefits 'far outweigh' risks: CDC
The benefits of the
Johnson & Johnson Covid-19 vaccine far outweigh its potential risks
amid an ongoing review of reports of a rare neurological disorder, according to
an advisory panel to the US Centers for Disease Control and Prevention (CDC) on
Thursday.
There have been 8.1 cases of
Guillain-Barre syndrome per 1 million doses, which is higher than expected in
the general population and close to eight times the rate seen in Pfizer's and
Moderna's shots, according to data presented at a meeting of CDC's Advisory
Committee on Immunization Practices on Thursday.
Guillain-Barre is a neurological disorder in
which the body's immune system damages nerve cells, causing muscle weakness and
sometimes paralysis, according to the US Food and Drug Administration (FDA).
The data came after the US Food and Drug
Administration (FDA) announced a new warning on July 12 for the Johnson &
Johnson shot after preliminary reports of Guillain-Barre syndrome in some
recipients, the Xinhua news agency reported. Read
More
Comments
Post a Comment